ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
66,963.25
0.03%
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs Yen
155.675
0.00%
Brent Oil
83.76
0.00%
Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Akero Therapeutics Inc (AKRO)

  7. Akero Therapeutics Inc (AKRO) ニュース

AKRO

Akero Therapeutics (AKRO)

Akero Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:AKRO
日付受信時刻ニュースソース見出しコード企業名
2024/05/1105 : 57Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:AKROAkero Therapeutics Inc
2024/05/1020 : 30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AKROAkero Therapeutics Inc
2024/05/1020 : 17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKROAkero Therapeutics Inc
2024/05/1020 : 00GlobeNewswire Inc.Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AKROAkero Therapeutics Inc
2024/05/0820 : 00GlobeNewswire Inc.Akero Therapeutics to Present at the BofA Securities 2024 Health Care ConferenceNASDAQ:AKROAkero Therapeutics Inc
2024/04/3021 : 00GlobeNewswire Inc.Akero Therapeutics Appoints Scott Gangloff as Chief Technology OfficerNASDAQ:AKROAkero Therapeutics Inc
2024/03/0906 : 02GlobeNewswire Inc.Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesNASDAQ:AKROAkero Therapeutics Inc
2024/03/0806 : 01GlobeNewswire Inc.Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and HepatologyNASDAQ:AKROAkero Therapeutics Inc
2024/03/0710 : 14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKROAkero Therapeutics Inc
2024/03/0710 : 13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKROAkero Therapeutics Inc
2024/03/0707 : 25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKROAkero Therapeutics Inc
2024/03/0707 : 16Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:AKROAkero Therapeutics Inc
2024/03/0611 : 13GlobeNewswire Inc.Akero Therapeutics Announces Pricing of Public Offering of Common StockNASDAQ:AKROAkero Therapeutics Inc
2024/03/0607 : 16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKROAkero Therapeutics Inc
2024/03/0520 : 05IH Market NewsAMD Hits Regulatory Roadblock, GitLab’s Stock Tumbles on Disappointing Earnings, and Latest NewsNASDAQ:AKROAkero Therapeutics Inc
2024/03/0507 : 34Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AKROAkero Therapeutics Inc
2024/03/0507 : 30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AKROAkero Therapeutics Inc
2024/03/0507 : 21Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:AKROAkero Therapeutics Inc
2024/03/0506 : 21GlobeNewswire Inc.Akero Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:AKROAkero Therapeutics Inc
2024/03/0421 : 55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKROAkero Therapeutics Inc
2024/03/0420 : 00GlobeNewswire Inc.Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY StudyNASDAQ:AKROAkero Therapeutics Inc
2024/03/0106 : 42Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AKROAkero Therapeutics Inc
2024/02/2922 : 00GlobeNewswire Inc.Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASHNASDAQ:AKROAkero Therapeutics Inc
2024/02/2921 : 30Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:AKROAkero Therapeutics Inc
2024/02/2921 : 15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKROAkero Therapeutics Inc
2024/02/2921 : 00GlobeNewswire Inc.Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:AKROAkero Therapeutics Inc
2024/02/1411 : 40Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:AKROAkero Therapeutics Inc
2024/01/0407 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKROAkero Therapeutics Inc
2024/01/0322 : 15GlobeNewswire Inc.Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:AKROAkero Therapeutics Inc
2023/12/3010 : 30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKROAkero Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:AKRO

最近閲覧した銘柄

TSX
NVO.WT.A
Novo Resources
BIT
GOL1S
Sg Etc Daily Short -1x G...
USOTC
IRCDF
Intercede (PK)
USOTC
DRRKF
Dormakaba (PK)
ASX
MGGDA
Mogul Games
LSE
V3SP
Vanesgucbga
LSE
SPEP
Ivz S&p Esg
USOTC
AVCNF
Avicanna (QX)
BIT
UB3JTN
UniCredit Bank
AMEX
FTVA
Aptus Fortified Value ETF
NASDAQ
FDMBBX
Sabrient Small Cap Growt...
EU
IHIES
HSBC HIES INAV
LSE
93TJ
Anz Bank 31
ASX
HFRJOA
LSE
19WS
Nat.grid 40
EU
FRBM
CAC Basic Mater
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有